SSX-4 peptides presented by HLA class II molecules

Details SSX-4 peptides presented by HLA class II molecules SSX-4 peptides presented by HLA class II molecules

2004-09-09

2010-12-28

Huff, Sheela J (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Reexamination Certificate

active

07858743

ABSTRACT:
The invention describes HLA class II binding peptides encoded by the SSX-4 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-4 gene.

REFERENCES:
patent: 5965535 (1999-10-01), Chaux et al.
patent: 6548064 (2003-04-01), Tureci et al.
patent: WO 0281646 (2002-10-01), None
patent: WO 02081646 (2002-10-01), None
Kersh, G.J., Miley, M.J., Nelson, C.A., Grakoui, A., Horvath, S., Donermeyer, D.L., Kappler, J., Allen, P.M., and Fremont, D.H. Structural and functional consequences of altering a peptide MHC anchor residue. Journal of Immunology, 2001. vol. 166, pp. 3345-3354.
Li, Y., Zhu, X., Huang, Y., and Xiong, H. Mutational analysis of the binding of staphylococcal enterotoxin D to the T cell receptor VB chain and major histocompatibility complex class II. Immunology Letters, 2006. vol. 105, pp. 55-60.
Gure et al. (International Journal of Cancer 1997; 72:965-971).
Brodin et al. (Gene 2001; 268: 173-182).
Gure et al. (International Journal of Cancer 2002; 101: 448-453).
Allsopp, C.E. et al., 1996, Comparison of numerous delivery systems for the induction of cytoxic T lymphocytes by immunization,Eur. J. Immunol. 26(8):1951-1959.
Altman, J.D. et al., 1996, Phenotypic analysis of antigen-specific T lymphocytes,Science274:94-96.
Arnold, P.Y. et al. 2002, Reliable generation and use of MHC class II:gamma2aFc multimers for the identification of antigen-specific CD4(+) T cells,J. Immunol. Methods271(1-2):137-151.
Bennett, S.R. et al., 1998, Help for cytotoxic—T cell responses is medicated by CD40 signalling,Nature393:478-480.
Brett,D. et al., 1997, The SYT protein involved in the t(X;18) synovial sarcoma translocation is transcriptional activator localised in nuclear bodies,Hum Mol Genet, 6(9):1559-1564.
Brodin, B. et al., 2001, Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4,SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expression,Gene, 262:173-182.
Calabresi, P. et al. Antineoplastic Agents, 1202-1263 Chapter 52, Rall, T.W., in Goodman and Gilman's “The Pharmacological basis of Therapeutics”, 8thEd., Taylor, P., Nies, A.S., Alfred Goodman Gilman, Eds., McGraw-Hill, 1990.
Clark, J. et al., 1994, Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma,Nat Genet, 7:502-508.
Crawford, F. et al., 1998, Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes,Immunity8:675-682.
De Bruijn, D.R. et al, 2002, The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX21P,Genes Chromosomes&Cancer, 34:285-298.
De Leeuw, B. et al, 1996, A Novel Krüppel-associated box containing the SSX gene (SSX3) on the human X chromosome is not implicated in t(X:18)-positive synovial sarcomas,Cytogenet Cell Genet, 73: 179-183.
Dunbar, P.R. et al, 2002, Oligomeric MHC molecules and their homologues; state of the art,J. Immunol. Methods268(1):3-7.
Dunbar, P.R. et al, 1998, Direct isolation, phenotyping and cloning of low-frequency antigen specific cytoxic T lymphocytes from peripheral blood,Curr. Biol. 8:413-416.
Fenton, R.G. et al., 1998, Induction of melanoma antigen-specific cytoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines,J. Immunother., 21 (2):95-108.
Gajewski, T. F. et al., 1995, Costimulation with B7-1, IL-6 and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro,J. Immunol. 154:5637-5648.
Glennie, M.J. et al, 2000, Clinical trials of antibody therapy.Immunol Today, 21:403-410.
Greenberg, P.D., 1991 Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells,Adv Immunol, 49:281-355.
Hall, S.S., 1995, IL-12 at the crossroads,Science268: 1432-1434.
Hugues, S. et al., 2002, Generation and use of alternative multimers of peptide/MHC complexes,J. Immunological Meth. 268: 83-92.
Hutloff, A et al., 1999, ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,Nature397:263-266.
Kim, J.J. et al., 1997 Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes,Nature Biotechnol. 15:7:641-646.
Krieg, A.M. et al., 1995, CpG motifs in bacterial DNA trigger direct B-cell activation,Nature374:546-9.
Kwok, W.W. et al., 2002, Use of class II tetramers for identification of CD4+ T cells,J Immunol Methods, 268:71-81.
MacBeath, G. et al, 2000, “Printing Proteins as Microarrays for High-Throughput Function Determination,”Science289: 1760-1763.
Nachman,R.J et al., 1995, Pseudodipeptide analogs of pyrokinin/PBAN (FXPRLa) insect neuropeptide family containing carbocyclic Pro-mimetic conformational components,Regul, Pept. 57:359-370.
Old, L.J., 1996 Immunotherapy for cancer,Sci Am, 275:136-143.
Parra, E et al., 1997, The role of B7-1 and LFA-3 in costimulation of CD8+T cells,J Immunol., 158:637-642.
Rammensee, H. et al., 1999, SYFPEITHI: database for MHC ligands and peptide motifs,Immunogenetics, 50:213-219.
Ridge, J.P. et al., 1998, A conditioned dendritic cell can be a temporal bridge between a CD4+T helper and a T-killer cell,Nature393; 474-478.
Sandberg, A.A. et al, 2002, Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma,Cancer Genet Cytogent, 133:1-23.
Schoenberger, S.P. et al., 1998, T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions,Nature393:480-483.
Schultz-Thater, E. et al., 2000, NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable b specific monoclonal antibodies in cell lines and clinical specimens,Br. J Cancer, 83(2):204-208.
Sercarz, E.E. et al., 1993, Dominance and crypticity of T cell antigenic determinants,Annu. Rev. Immunol., 11:729-766.
So, H.S. et al., 1997, Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen,Mol. Cells7:178-186.
Stephens, H.A.F. et al., 1995, The presence of HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen,Eur J Immunol, 25:3142-3147.
Ulmer, J.B. et al., 1993, Heterologous protection against influenza by injection of DNA encoding a viral protein,Science, 259:1745-1749.
Wang Y.C. et al., 1996, Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell lime by B7-1 (CD8O) costimulation,J Immunother Emphasis Tumor Immunol., 19(1):1-8.
Warnier, G. et al, 1996, Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A,Int. J. Cancer, 67:303-310.
Ayyoub, Maha, et al., CD4+ T Cell responses to SSX-4 in Melanoma Patients,The Journal of Immunology, Copyright 2005, The American Association of Immunologies, Inc., pp. 5092-5099.
Ayyoub, M. et al. 2004, An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR,J Clin Invest113: 1225-33.
Ayyoub, M et al., 2004, Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells,J. Immunol172:7206-7211.
Ayyoub, M. et al., 2002, Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastic melanoma,J Immunol, 168:1717-1722.
Ayyoub, M. et al., 2003, SSX antigens as tumor vaccine targets in human sarcoma,Cancer Immunity, 3:13.
Ayyoub, M. et al., 2003, Tumor-reactive SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen expressing tumors in melanoma patients,Cancer Res, 63:5601-5606.
Ayyoub, M. et al., 2005, CD4+T cell responses to SSX-4 in melanoma patients,J

Affiliated with

Also associated with

Rating

SSX-4 peptides presented by HLA class II molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SSX-4 peptides presented by HLA class II molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SSX-4 peptides presented by HLA class II molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4171517